Journal
GYNECOLOGICAL ENDOCRINOLOGY
Volume 32, Issue 8, Pages 612-616Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/09513590.2016.1145647
Keywords
Anti-androgen therapy; anti-mullerian hormone; cyproterone acetate; oral contraceptive pill; polycystic ovary syndrome
Ask authors/readers for more resources
Objective: To compare the suppressive effect of anti-androgen therapy by cyproterone acetate (CPA) and by oral contraceptive pill (OCP) on anti-mullerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) in order to detect a putative direct anti-androgen effect on AMH excess. Methods: This is a prospective longitudinal study including 58 women with PCOS between January 2010 and April 2014 at the Lille University Hospital. A total of 47 women with clinical hyperandrogenism were treated by CPA (50 mg/d was administered 20 days out of 28) and 11 women with PCOS but without clinical hyperandrogenism received OCP. Result(s): Serum AHM levels at baseline were similar in CPA and OCP groups (median [5-95th percentiles]: 60.4 pmol/l [25.1-200.2] versus 58 pmol/l [27.6-100], respectively, p = 0.39). After 3 months of treatment, serum AMH levels decreased significantly by 28% +/- 20% and by 22% +/- 27% in CPA and OCP groups, respectively. The decrease under both treatments was similar (p = 0.48). Conclusion(s): That any anti-androgen effect could be observed on AMH in our CPA group in addition to the gonadotropin-suppressing effect suggests that either androgens are not involved in AMH regulation or that they act by interfering with gonadotropin effects on granulosa cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available